Front-Line Therapy for Chronic Lymphocytic Leukemia

被引:2
|
作者
Desai, Sheetal [1 ]
Pinilla-Ibarz, Javier [2 ]
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pharm, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
关键词
FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; PREVIOUSLY UNTREATED PATIENTS; 1ST-LINE THERAPY; CLINICAL ACTIVITY; RESIDUAL DISEASE; RITUXIMAB; ALEMTUZUMAB; CHEMOIMMUNOTHERAPY;
D O I
10.1177/107327481201900104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Historically, alkylator-based therapy has been used to treat patients with chronic lymphocytic leukemia (CLL). More effective therapies, such as the use of monoclonal antibodies in combination with chemotherapy, have been shown to prolong both progression-free survival and overall survival. Improvements in the identification of prognostic markers for CLL, as well as novel combinations for chemoimmunotherapy regimens, have improved the outcome for patients with CLL. Methods: We examine the diagnosis of CLL, the role of prognostic factors in determining treatment goals, and current data on front-line management of CLL. Results: The benefits of single-agent and combination therapies are associated with prolonged progression-free and overall survival. While more aggressive management may therefore be warranted, each patient's comorbidities and performance status must be weighed against the benefits, availability, cost, treatment goals, and incidence of adverse effects associated with each therapy. Conclusions: New single agents and novel treatment combinations have shown promising results in phase I/II studies. The ultimate therapeutic goals of prolonged survival and improved quality of life will be validated only by ongoing clinical and laboratory research and by continuous enrollment of patients in clinical trials.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 50 条
  • [21] Fine-tuning front-line therapy in chronic lymphocytic leukemiaNews from ASH 2019
    Jan-Paul Bohn
    Dominik Wolf
    [J]. memo - Magazine of European Medical Oncology, 2020, 13 : 259 - 265
  • [22] Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center
    Arguello-Tomas, Miguel
    Albiol, Nil
    Jara, Paola
    Sierra, Jordi
    Mora, Alba
    Moreno, Carol
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S280
  • [23] The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients
    Rhodes, Joanna
    Barr, Paul M.
    Ujjani, Chaitra S.
    Nabhan, Chadi
    Tam, Constantine S.
    Jacobs, Ryan
    Lansigan, Frederick
    Hill, Brian T.
    Brander, Danielle M.
    Shadman, Mazyar
    Skarbnik, Alan P.
    Pu, Jeffrey J.
    Sehgal, Alison R.
    Pagel, John M.
    Allan, John N.
    Kennard, Kaitlin
    Cheson, Bruce D.
    Beach, Douglas F.
    Patel, Bhavisha
    Isaac, Krista
    Tuncer, Hande H.
    Furman, Richard R.
    Mato, Anthony R.
    [J]. BLOOD, 2017, 130
  • [24] Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis
    Xu, Yingxin
    Fahrbach, Kyle
    Dorman, Emily
    Baculea, Simona
    Cote, Sarah
    van Sanden, Suzy
    Diels, Joris
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (05) : 421 - 441
  • [25] Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    Sirard, C.
    Mayer, J.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 46
  • [26] EFFICACY AND SAFETY OF FLUDARABINE AND CYCLOPHOSPHAMIDE REGIME AS FRONT-LINE THERAPY IN PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA WITH LOW RISK BIOLOGICAL PARAMETERS
    Laurenti, L.
    Laurenti, L.
    De Padua, L.
    Tarnani, M.
    Piccirillo, N.
    Falcucci, P.
    D'Arena, G.
    Innocenti, I.
    Marietti, S.
    Efremov, D.
    Chiusolo, P.
    Zini, G.
    Rumi, C.
    Sica, S.
    Leone, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 524 - 525
  • [27] Erratum: High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review
    T Reljic
    A Kumar
    B Djulbegovic
    M A Kharfan-Dabaja
    [J]. Bone Marrow Transplantation, 2015, 50 : 1144 - 1144
  • [28] Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
    Lampson, Benjamin L.
    Kasar, Siddha N.
    Matos, Tiago R.
    Morgan, Elizabeth A.
    Rassenti, Laura
    Davids, Matthew S.
    Fisher, David C.
    Freedman, Arnold S.
    Jacobson, Caron A.
    Armand, Philippe
    Abramson, Jeremy S.
    Arnason, Jon E.
    Kipps, Thomas J.
    Fein, Joshua
    Fernandes, Stacey
    Hanna, John
    Ritz, Jerome
    Kim, Haesook T.
    Brown, Jennifer R.
    [J]. BLOOD, 2016, 128 (02) : 195 - 203
  • [29] Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
    Massimo Gentile
    Tait D. Shanafelt
    Gianluigi Reda
    Francesca Romana Mauro
    Katja Zirlik
    Stefania Ciolli
    Luca Laurenti
    Maria Ilaria Del Principe
    Davide Rossi
    Nicola Di Renzo
    Stefano Molica
    Francesco Angrilli
    Marta Coscia
    Annalisa Chiarenza
    Annamaria Giordano
    Giovanna Cutrona
    Kari G. Chaffee
    Sameer A. Parikh
    Giuseppina Uccello
    Idanna Innocenti
    Giovanni Tripepi
    Graziella D’Arrigo
    Ernesto Vigna
    Anna Grazia Recchia
    Yair Herishanu
    Lev Shvidel
    Tamar Tadmor
    Agostino Cortelezzi
    Giovanni Del Poeta
    Gianluca Gaidano
    Francesco Di Raimondo
    Antonino Neri
    Manlio Ferrarini
    Robin Foà
    Aaron Polliack
    Fortunato Morabito
    [J]. Leukemia, 2018, 32 : 1869 - 1873
  • [30] Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study
    Wallington, Michael
    Guillaume, Xavier
    Mulvihill, Emily
    Wayser, Graceanne R.
    Kaul, Vandana
    Graziani-Taugeron, Claire
    Shahkarami, Mina
    Ryan, Kellie J.
    [J]. BLOOD, 2022, 140 : 10810 - 10811